Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Milliman Care Guidelines honors Sound Physicians with prestigious award

Sound Physicians, a leading hospitalist organization focused on driving improvements in quality, satisfaction and efficiency of inpatient healthcare delivery, today received the Doyle Award for Innovation and Leadership in Healthcare.

6 Apr 2011

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

Aragen Bioscience, Inc., today announced it is a subcontractor on a National Institute of Allergy and Infectious Diseases contract for the preclinical development of monoclonal antibodies for the prevention and treatment of infectious diseases.

6 Apr 2011

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme Corp., a subsidiary of sanofi-aventis Group, and Isis Pharmaceuticals Inc. announced today that data from two phase 3 studies of mipomersen in patients who had high cholesterol levels while on lipid-lowering therapy were presented at the American College of Cardiology's 60th Annual Scientific Session.

6 Apr 2011

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

NanoViricides, Inc. reports that post-infection treatment with its optimized FluCide™ drug candidates resulted in dramatic reduction in the number of lung lesions that are caused by a lethal influenza virus infection. These findings were seen in the most recent H1N1 influenza animal study.

5 Apr 2011

Milliman Care Guidelines presents Doyle Award to ADVANTAGE Health Solutions and Sound Physicians

Milliman Care Guidelines today presented its Doyle Award for Innovation and Leadership in Healthcare to ADVANTAGE Health Solutions, Inc.(SM) and to Sound Physicians. The awards were presented in ceremonies here at the Milliman Care Guidelines Client Forum.

5 Apr 2011

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

Novavax, Inc. announced that its virus-like particle (VLP) influenza vaccine has been named by the editors of R&D Directions magazine as one of the top "100 great investigational drugs in development" today. In its tenth annual list of promising clinical compounds, R&D Directions cited Novavax's virus-like-particle technology as a promising new approach to producing vaccines to prevent seasonal, H1N1 and avian influenza. The list reflects the current interests of industry observers and analysts and is described in the magazine's March 2011 issue.

5 Apr 2011

The New England Journal of Medicine publishes positive results from NorthShore's EVEREST II trial

NorthShore University HealthSystem interventional cardiologist, Ted Feldman, MD, presented positive results from the EVEREST II trial, that were concurrently published in The New England Journal of Medicine.

5 Apr 2011

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene,a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that new data from Phase 1 and 2 clinical studies of JX-594 were presented in an oral presentation at the 46th Annual Meeting of the European Association for the Study of the Liver over the weekend at the Internationales Congress Centrum in Berlin, Germany.

5 Apr 2011

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Cubist Pharmaceuticals, Inc. today announced that it has entered into a license agreement with Teva Parenteral Medicines, Inc., Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd., which includes a stipulation by the parties requesting dismissal of the lawsuit filed by Cubist in the U.S. District Court for the District of Delaware relating to the Abbreviated New Drug Application filed by TPM with the U.S. Food and Drug Administration for a generic version of CUBICIN.

5 Apr 2011

Statins can help prevent risk of death from pneumonia

Taking statins could help prevent people dying from pneumonia, according to a study by the London School of Hygiene and Tropical Medicine.

5 Apr 2011

Study suggests causal link between HSV1 and Alzheimer's disease

Laboratories at the University of New Mexico (UNM), Brown University, and House Ear Institute (HEI) have developed a new technique to observe herpes simplex virus type 1 (HSV1) infections growing inside cells. HSV1, the cause of the common cold sore, persists in a latent form inside nerve cells.

5 Apr 2011

State Roundup: Budget cuts in Texas, Wash. State; Ariz. smoking, weight fees; Coping with Rx drug abuse

The Texas House voted 98-49 Sunday night to slash funding for public schools, nursing homes and college financial aid in a dramatic show by Republicans elected on a limited-government message in the face of a massive budget shortfall.

4 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

OncoSec acquires certain assets of Inovio

OncoSec Medical Incorporated, a developer of innovative medical approaches to treat solid tumor cancers with unmet medical needs, announced today that on March 24, 2011 it completed its acquisition of certain assets of Inovio Pharmaceuticals, Inc. and entered into a license agreement with Inovio, pursuant to the terms of an asset purchase agreement with Inovio entered into on March 14, 2011.

4 Apr 2011

Experts to discuss on healthcare-associated infection at SHEA Annual Meeting

A special media phone briefing with leading infectious disease scientists and healthcare-associated infection experts who will headline the 2011 Society for Healthcare Epidemiology of America's Annual Meeting

4 Apr 2011

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

Bristol-Myers Squibb Company today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response in genotypes 1, 2, 3, and 4, and complete early virologic response in genotypes 1 and 4 than the standard regimen of PEG-Interferon alfa and ribavirin in treatment-naïve patients chronically infected with hepatitis C.

4 Apr 2011

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Highly exciting new data presented today at the International Liver Congress found Pegylated Interferon-lambda shows superior virological response in HCV patients of genotypes 1-4, with improved safety and tolerability, compared to Pegylated Interferon-alpha, the current standard of care in chronic HCV.

4 Apr 2011

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Promising new viral hepatitis data presented today at the International Liver CongressTM show that entry inhibitors --a new mechanism of action for drugs to treat viral hepatitis -- could provide the first new hepatitis B and hepatitis D treatments for many years.

2 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Milliman Care Guidelines honors Sound Physicians with prestigious award

NIAID awards Aragen Bioscience with three subcontracts to advance preclinical studies

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Post-infection treatment with NanoViricides FluCide reduces lung lesions caused by lethal influenza infection

Milliman Care Guidelines presents Doyle Award to ADVANTAGE Health Solutions and Sound Physicians

R&D Directions names Novavax VLP influenza vaccine as one of top '100 great investigational drugs in development'

The New England Journal of Medicine publishes positive results from NorthShore's EVEREST II trial

Jennerex, Transgene present JX-594 Phase 1 and 2 study data in liver cancer at EASL meeting

Cubist enters license agreement with Teva to dismiss CUBICIN patent lawsuit

Statins can help prevent risk of death from pneumonia

Study suggests causal link between HSV1 and Alzheimer's disease

State Roundup: Budget cuts in Texas, Wash. State; Ariz. smoking, weight fees; Coping with Rx drug abuse

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

OncoSec acquires certain assets of Inovio

Experts to discuss on healthcare-associated infection at SHEA Annual Meeting

BMY announces PEG-Interferon lambda plus ribavirin Phase IIb trial results against HCV

New data finds PegIFN-lambda shows RVR in HCV patients with improved safety, tolerability

Entry inhibitors can provide first new hepatitis B & D treatments for many years

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Newsletters you may be interested in